ARN25699 is a kinase inhibitor with an IC50 of 5.5 nM against GSK-3beta, 2.2 nM against FYN-alpha, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimers disease. ARN25699 can be used in the research of Alzheimers disease and related tauopathies[1].
Molecular Weight:
403.44
Formula:
C21H21N7O2
Target:
DYRK,GSK-3,Microtubule/Tubulin,Src,Tau Protein
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
